Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Cognitive Dysfunction × Chemoradiotherapy × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Rectal Neoplasms 34 Esophageal Neoplasms 17 Carcinoma, Non-Small-Cell Lung 16 Squamous Cell Carcinoma of Head and Neck 15 Nasopharyngeal Carcinoma 10 Pancreatic Neoplasms 9 Head and Neck Neoplasms 9 Uterine Cervical Neoplasms 8 Oropharyngeal Neoplasms 8 Esophageal Squamous Cell Carcinoma 6 Neoplasms 5 Lung Neoplasms 5 Carcinoma, Squamous Cell 5 Urinary Bladder Neoplasms 4 Stomach Neoplasms 4 Mouth Neoplasms 4 Glioblastoma 4 Colorectal Neoplasms 4 Carcinoma 4 Adenocarcinoma 4 Pathologic Complete Response 3 Laryngeal Neoplasms 3 Hypopharyngeal Neoplasms 3 Breast Neoplasms 3 Thymoma 2 Resectable Esophageal Cancer 2 Radiation Injuries 2 Neoplasms by Site 2 Nasopharyngeal Neoplasms 2 NSCLC 2

Interventions

Exercise 6 Transcranial Direct Current Stimulation 4 Neuropsychological Tests 4 Walking 3 Memantine 3 Tablets 2 Standard of Care 2 Patient Reported Outcome Measures 2 Methods 2 Electroencephalography 2 Drug Therapy 2 Donepezil 2 Cognitive Behavioral Therapy 2 mazdutide 1 lithium sulfate 1 lime 1 enzalutamide 1 blueberry extract 1 beta Carotene 1 acetaminophen, aspirin, caffeine drug combination 1 XENP 1595 1 Waiting Lists 1 Vitamin E 1 Vitamin D 1 Ultraviolet Therapy 1 Time 1 Tai Ji 1 Surveys and Questionnaires 1 Sugars 1 Sodium Chloride 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06551857 2025-04-16

CaSPiN

Turku University Hospital

Ototoxicity, Neoplasms, Hearing Loss, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon ⚡